+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Brain Metastasis from Breast Cancer - Pipeline Insight, 2020

  • ID: 5215134
  • Drug Pipelines
  • December 2020
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Abbott
  • Angiochem
  • Cortice Biosciences
  • Ipsen
  • Merck & Co.
  • Northwest Biotherapeutics
This “Brain Metastasis from Breast Cancer - Pipeline Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Brain Metastasis from Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Brain Metastasis from Breast Cancer Understanding

Brain Metastasis from Breast Cancer: Overview

Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10-16 % of patients. The development of brain metastases is a complex process, requiring invasion of the primary breast cancer cells into surrounding tissue and vessels, traffic through the circulatory system and colonization and growth in the brain parenchyma. The incidence of BMs is increasing due to both improved diagnostic techniques (e.g. magnetic resonance imaging: (MRI)) and increased cancer patient survival through advanced systemic treatment approaches. Brain metastases from Breast cancer represent an unmet medical need in solid tumor care.

Symptoms

The symptoms of Brain Metastasis from Breast Cancer include:
  • headache
  • changes in senses controlled by the brain such as slurred speech, blurred vision, balance problems, dizziness, or anything else that seems unusual
  • memory problems
  • mood or personality changes
  • seizures
  • stroke or “brain attack,” in which blood supply to the brain is cut off
Diagnosis

Diagnosis can be done through MRI (magnetic resonance imaging) study of the brain.In rare cases, biopsies are performed to confirm the diagnosis. Neuroimaging, staging, and diagnostic neuropathology can also be done.

Treatment

The most common treatments for metastatic breast cancer in any location (bone, brain, lung, or liver) are systemic medications, which treat cancer throughout the entire body. Current therapies for Brain Metastasis from Breast Cancer include surgery, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy, immunotherapy, and targeted therapies. Under chemotherapy, etirinotecan pegol has promising results and in Abemaciclib as a targeted therapies can also be seen. Lapatinib, a small molecule with potential ability to cross the BBB, has been extensively tested in the treatment of HER2-positive brain metastases.

Brain Metastasis from Breast Cancer Emerging Drugs Chapters

This segment of the Brain Metastasis from Breast Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Brain Metastasis from Breast Cancer Emerging Drugs

ANG-1005: Angiochem

ANG-1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2). The drug gains entry into the brain by targeting the LRP-1, which is one of the most highly-expressed receptors on the surface of the Blood brain barrier. Once inside the brain, ANG1005 enters tumor cells using the same receptor-mediated pathway through LRP-1, which is upregulated in various cancer cells including malignant glioma and metastatic cancers in the brain.

Neratinib: Puma Biotechnology

Neratinib is a kinase inhibitor and is under Phase II development for the treatment of HER2-positive metastatic breast cancer that has metastasized to the brain. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4.

Brain Metastasis from Breast Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Brain Metastasis from Breast Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Brain Metastasis from Breast Cancer

There are approx. 10+ key companies which are developing the therapies for Brain Metastasis from Breast Cancer. The companies which have their Brain Metastasis from Breast Cancer drug candidates in the most advanced stage, i.e. phase II include, Puma Biotechnology.

Phases

This report covers around 10+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Brain Metastasis from Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Brain Metastasis from Breast Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Brain Metastasis from Breast Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Brain Metastasis from Breast Cancer drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Brain Metastasis from Breast Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Brain Metastasis from Breast Cancer.
Brain Metastasis from Breast Cancer Report Insights
  • Brain Metastasis from Breast Cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Brain Metastasis from Breast Cancer Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Brain Metastasis from Breast Cancer drugs?
  • How many Brain Metastasis from Breast Cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Brain Metastasis from Breast Cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Brain Metastasis from Breast Cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Brain Metastasis from Breast Cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Angiochem
  • Northwest Biotherapeutics
  • Merck & Co.
  • Novartis Pharmaceuticals
  • Abbott
  • Ipsen
  • Puma Biotechnology
  • Cortice Biosciences
  • Onconova Therapeutics
Key Products
  • ANG-1005
  • DCVax®-Direct
  • Pembrolizumab
  • BKM120
  • Everolimus
  • Irinotecan sucrosofate
  • Neratinib
  • TPI 287
  • ON 123300

This report will be delivered within 1-3 business days
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott
  • Angiochem
  • Cortice Biosciences
  • Ipsen
  • Merck & Co.
  • Northwest Biotherapeutics
Introduction

Executive Summary

Brain Metastasis from Breast Cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Brain Metastasis from Breast Cancer- Analytical Perspective

In-depth Commercial Assessment
  • Brain Metastasis from Breast Cancer companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Brain Metastasis from Breast Cancer Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Mid Stage Products (Phase II)
  • Comparative Analysis
ANG-1005: Angiochem
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
DCVax®-Direct: Northwest Biotherapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Pre-clinical and Discovery Stage Products
  • Comparative Analysis
ON 123300: Onconova Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Brain Metastasis from Breast Cancer Key Companies

Brain Metastasis from Breast Cancer Key Products

Brain Metastasis from Breast Cancer- Unmet Needs

Brain Metastasis from Breast Cancer- Market Drivers and Barriers

Brain Metastasis from Breast Cancer- Future Perspectives and Conclusion

Brain Metastasis from Breast Cancer Analyst Views

Brain Metastasis from Breast Cancer Key Companies

Appendix

List of Tables
Table 1 Total Products for Brain Metastasis from Breast Cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Brain Metastasis from Breast Cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Angiochem
  • Northwest Biotherapeutics
  • Merck & Co.
  • Novartis Pharmaceuticals
  • Abbott
  • Ipsen
  • Puma Biotechnology
  • Cortice Biosciences
  • Onconova Therapeutics
Note: Product cover images may vary from those shown
Adroll
adroll